BUSINESS

• Pexidartinib Delivers Significant ORR in PIII: Daiichi Sankyo
  June 6, 2018

• Takeda’s Founding Family-Backed Shareholders Demand Prior Vote for 1 Trillion Yen-Plus Deals
  June 6, 2018

• AbbVie Japan Seeks Hidradenitis Suppurativa Nod for Humira
  June 6, 2018

• Yakult Honsha Obtains Rights to Hematologic Cancer Agent from US Biopharma
  June 6, 2018

• Rxulti Earns European Panel Nod for Schizophrenia: Otsuka/Lundbeck
  June 5, 2018

• FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
  June 5, 2018

• AstraZeneca Japan Settles All Labor Suits
  June 4, 2018

• Meiji Seika Pharma Chief Sounds Negative about Authorized Generic Biz
  June 4, 2018

• JCR to Launch Japan PIII for BBB-Penetrating Hunter Syndrome Drug
  June 4, 2018

• FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
  June 4, 2018

• Japan Drug Makers See Rising Overseas Sales Ratio amid Uphill Battle at Home: Tally
  June 1, 2018

• Daiichi Sankyo Kicks Off PII for DS-8201 in NSCLC
  June 1, 2018

• Shionogi Grabs Rights to Hsiri’s Mycobacterial Disease Therapies
  June 1, 2018

• Roxadustat Hits Primary Endpoint in Japan PIII: Astellas/FibroGen
  June 1, 2018

• FDA Accepts Eisai’s Fycompa for Pediatric Indication Review
  June 1, 2018

• Astellas Files Japan NDA for JAK Inhibitor Peficitinib in RA
  June 1, 2018

• Kissei’s Spinocerebellar Ataxia Treatment Fails to Hit Primary Targets in Japan PIII Study
  June 1, 2018

• 3 Japan Drug Makers Launch Industry-Academia Consortium on Drug Discovery for Immune-Mediated Inflammatory Diseases
  June 1, 2018

• Takeda Licenses Relugolix to ASKA in Women’s Health Field
  June 1, 2018

• Perspective on Takeda/Shire Deal - 3: Takeda Shareholders Got Short End of the Stick
  May 31, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 383
• 384
• 385
• 386
• 387
• 388
• 389
• 390
• 391
• …
• Next ›
• 最終 »